Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims focus on a three-gene biomarker signature comprising elevated expression of PTGR1, PTPN14, and ASPH to identify patients likely to benefit from LP-184 treatment.
The company's proprietary RADR artificial intelligence platform played a key role in identifying this biomarker signature, underscoring Lantern's commitment to precision medicine. In its Phase 1a trial, LP-184 demonstrated a 45% disease control rate among patients treated at or above the effective therapeutic dose. Lantern plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. More details can be found in the full press release at https://ibn.fm/LRGUo.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI and machine learning through its RADR platform to transform cancer therapy development. Its pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Additionally, Lantern's withZeta.ai, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For the latest news and updates, visit the company's newsroom at https://ibn.fm/LTRN.
